ATARA BIOTHERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Revenue from Contract with Customer, Including Assessed Tax of $120.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-03-16
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-12-31 was $32.75M, a 670.30% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-09-30 was $40.19M, a 1779.79% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-06-30 was $28.64M, a 2892.69% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2024-03-31 was $27.36M, a 2131.40% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $120.77M, a 6.33% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $128.94M, a 1404.02% increase from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $8.57M, a 86.51% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $63.57M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $120.77M 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $32.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $72.94M derived: sum of 2 quarters · filed 2026-03-16 | $101.58M derived: sum of 3 quarters · filed 2026-03-16 | $128.94M 10-K · filed 2026-03-16 |
| 2024-09-30 | $40.19M 10-Q · filed 2024-11-12 | $68.83M derived: sum of 2 quarters · filed 2024-11-12 | $96.19M 10-Q · filed 2024-11-12 | $100.44M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $28.64M 10-Q · filed 2024-08-12 | $56.00M 10-Q · filed 2024-08-12 | $60.25M derived: sum of 3 quarters · filed 2025-03-07 | $62.39M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $27.36M 10-Q · filed 2024-05-09 | $31.61M derived: sum of 2 quarters · filed 2025-03-07 | $33.75M derived: sum of 3 quarters · filed 2025-03-07 | $34.70M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $6.39M derived: sum of 2 quarters · filed 2025-03-07 | $7.35M derived: sum of 3 quarters · filed 2025-03-07 | $8.57M 10-K · filed 2025-03-07 |
| 2023-09-30 | $2.14M 10-Q · filed 2024-11-12 | $3.10M derived: sum of 2 quarters · filed 2024-11-12 | $4.32M 10-Q · filed 2024-11-12 | $4.54M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $957.00K 10-Q · filed 2024-08-12 | $2.18M 10-Q · filed 2024-08-12 | $2.40M derived: sum of 3 quarters · filed 2024-08-12 | $6.86M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $1.23M 10-Q · filed 2024-05-09 | $1.45M derived: sum of 2 quarters · filed 2024-05-09 | $5.91M derived: sum of 3 quarters · filed 2024-05-09 | $57.48M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.68M derived: sum of 2 quarters · filed 2024-03-28 | $56.26M derived: sum of 3 quarters · filed 2024-03-28 | $63.57M 10-K · filed 2024-03-28 |
| 2022-09-30 | $4.46M 10-Q · filed 2023-11-01 | $56.04M derived: sum of 2 quarters · filed 2023-11-01 | $63.35M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $51.58M 10-Q · filed 2023-08-08 | $58.89M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $7.31M 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |